Literature DB >> 10741794

Evaluation of new sclerotic bone metastases in breast cancer patients during treatment.

I Ciray1, G Aström, I Andréasson, T Edekling, J Hansen, J Bergh, H Ahlström.   

Abstract

PURPOSE: According to the World Health Organization (WHO) criteria for response of bone metastases to therapy, new lesions indicate progressive disease. We intended to prove that a new sclerotic lesion on conventional radiography may also be a sign of a positive therapeutic response in a previously undetectable lytic metastasis.
MATERIAL AND METHODS: In a previous placebo-controlled clinical trial of clodronate (Ostac) therapy, 139 breast cancer patients with bone metastases underwent both conventional radiography and bone scan every 6 months for 2 years with 99mTc before and during clodronate treatment. WHO criteria were applied for therapy response evaluation.
RESULTS: In 24 patients, 52 new sclerotic lesions observed during therapy were selected for re-evaluation of conventional radiographs and bone scans. In 8 of the 24 patients, 17 of 52 new sclerotic lesions (33%) had showed positive uptake on previous bone scans. These lesions were possibly misinterpreted as new when applying WHO criteria.
CONCLUSION: For better assessment of new sclerotic lesions during treatment, more sensitive techniques, e.g. bone scan, are needed as a complement to conventional radiography.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741794     DOI: 10.1080/028418500127345019

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  5 in total

Review 1.  MRI for response assessment in metastatic bone disease.

Authors:  F E Lecouvet; A Larbi; V Pasoglou; P Omoumi; B Tombal; N Michoux; J Malghem; R Lhommel; B C Vande Berg
Journal:  Eur Radiol       Date:  2013-03-01       Impact factor: 5.315

2.  VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.

Authors:  Shirou Ishii; Ken Kikuchi; Masayuki Miyajima; Kotaro Sakuma; Fumio Shishido
Journal:  Fukushima J Med Sci       Date:  2015-05-03

Review 3.  Early-Onset Osteoporosis: Rare Monogenic Forms Elucidate the Complexity of Disease Pathogenesis Beyond Type I Collagen.

Authors:  Alice Costantini; Riikka E Mäkitie; Markus A Hartmann; Nadja Fratzl-Zelman; M Carola Zillikens; Uwe Kornak; Kent Søe; Outi Mäkitie
Journal:  J Bone Miner Res       Date:  2022-09-11       Impact factor: 6.390

Review 4.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

5.  Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer.

Authors:  Ismet Sarikaya; Abdelhamid Elgazzar; Ali Sarikaya; Mahmoud Alfeeli
Journal:  World J Nucl Med       Date:  2018 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.